Company: EUDAW
Filing Date: 2025-04-29
Form Type: 20-F
Source: 0001641172-25-006627
Chunk: 30

Company: EUDA Health Holdings Ltd
Filing Date: 2025-04-29
Form: 20-F
Item: Item 4
Chunk 30
---
 region’s
evolving healthcare needs through innovative, technology-driven solutions. EUDA’s strategy is anchored in wellness services, designed to deliver accessible, holistic, and transformative care.

EUDA
currently provides property management services and direct sales of bioenergy cabins therapy packages. Beginning late April 2025, it plans to start
selling stem cell therapy services rendered in third-party treatment centers in China.

EUDA
expanded its wellness services through the acquisition of CK Health in 2024, a Malaysia-based innovator specializing in proprietary bioenergy
cabins. These capsules designed to promote detoxification, enhance vitality, strengthen immune system function, and improve skin health
 - directly addressing the needs of Southeast Asia’s aging population, where one in five individuals is over 50 years of age.
CK Health plans to deploy 1,000 capsules across the region, with each capsule expected to support three one-hour sessions per day. This
initiative aligns with the growing demand for affordable, high-value wellness services.

On April 22, 2025, CK
Health entered into a collaboration agreement with Key Lock Health Management Co., Ltd. (“ Key Lock”), an authorized
distributor of Guangdong Cell Biotech Co. Ltd. (“ Guangdong Cell Biotech”), responsible for promoting and selling its
stem cell therapy packages, managing sales, market development and customer support. Pursuant to this collaboration agreement, CK
Health will purchase from Key Lock certain stem cell therapy services offered by Guangdong Cell Biotech at certain pre-determined
prices and market and sell these services in Singapore and Malaysia; and Key Lock will use its commercial endeavours to ensure
proper stem cell therapy services received by EUDA customers at one of Guangdong Cell Biotech’s treatment centers in China.
This collaboration agreement is terminable by either party with one month’s notice of termination. EUDA’s stem cell
therapy offering will focus on regenerative treatments for chronic illnesses, age-related degeneration, and tissue repair. This
combination will allow EUDA to serve consumers from daily wellness support to cutting-edge
therapeutic care.

  18  

Legal
Proceedings

On
May 12, 2023, there were disagreements between the directors and formers directors of the Company concerning, among others, the legitimacy
of:

  The                                                                                                                  
  The                                                                                                                  
  The                                                                                                                  
  The                                                                                                                  
  The                                                                                                                  
  The                                                                                                                  
  The                                                                                                                  

Upon
consultation with the Company’s external counsel, the